Charles Schwab YieldPlus Settlements and Damages Could Cost $1B: Report

Charles Schwab could face close to $1 billion in damages and settlements stemming from securities fraud lawsuits over their Schwab YieldPlus bond fund

In an earnings release issued by Charles Schwab Corp. last week, the company announced that it faces at least 194 individual stockbroker arbitration claims for up to $34 million, in addition to a YieldPlus Bond Fund class action lawsuit that looks to recoup $890 million for investors. In addition, other claims may still be filed against the brokerage firm over investment losses allegedly caused by their handling of the bond fund.

The Schwab YieldPlus funds are ultra-short bond funds that were heavily promoted as conservative investment alternatives to money market funds or cash. Despite being advertised to generate income with minimal changes in share price, the fund lost more than 30% of its value between June 2007 and June 2008 due to heavy investments in risky subprime mortgage securities, which some experts indicate violated the prospectus.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The funds lost much of their value when the sub-prime mortgage market crashed in late 2007, leaving investors with substantial losses. The investor claims allege that Schwab misled investors and failed to properly disclose the nature of the risks associated with certain securities held by the bond funds.

In October, Schwab announced that it had received a “Wells notice” from the U.S. Securities and Exchange Commission (SEC) indicating that they plan to recommend that the company be brought up on civil charges. No charges have yet been filed.

Earlier this month, a summary judgment from a federal judge in California determined that the company erred in failing to get investors’ approval before shifting half of the fund’s assets into mortgage-backed bonds. The ruling clears the way for the pending class action lawsuits for three classes of plaintiffs to proceed.

Two classes of plaintiffs are scheduled to go to trial on May 10.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

EU Launches Investigation Into Ozempic Vision Loss Problems
EU Launches Investigation Into Ozempic Vision Loss Problems (Posted 3 days ago)

Following nearly 20 reports of vision problems from Ozempic or Wegovy since a study was published in July 2024, Danish health officials are calling for an EU investigation into the safety of semaglutide-based drugs.